Platinum compound used in new lung cancer treatment
Oncology specialists Poniard Pharmaceuticals have successfully enrolled 75 patients in a trial for its new drug treatment for the aggressive small cell lung cancer (SCLC). The product called Picoplatin is an intravenous platinum-based chemotherapy drug that has been designed to overcome the problems normally associated with resistance in chemotherapy regimes using platinum compounds. Picoplatin is Poniard’s leading candidate for a treatment for SCLC, which is the most deadly and aggressive form of lung cancer accounting for roughly 20 per cent of all cases presented to US and European doctors.
This entry was posted on Wednesday, August 23rd, 2006 at 9:19 am and is filed under Research, Small-Cell. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.